Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Precision BioSciences
Deal Size : $555.0 million
Deal Type : Termination
Precision BioSciences Announces Return of Programs and End of Collaboration with Prevail
Details : Precision exercised its option to regain rights for the programs, including its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $100.0 million
April 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Precision BioSciences
Deal Size : $555.0 million
Deal Type : Termination
Lead Product(s) : Adeno-associated Virus Gene Therapy
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Sangamo Therapeutics
Deal Size : $1,190.0 million
Deal Type : Agreement
Details : Under the agreement, Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 17, 2023
Lead Product(s) : Adeno-associated Virus Gene Therapy
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Sangamo Therapeutics
Deal Size : $1,190.0 million
Deal Type : Agreement
Lead Product(s) : CRISPR-based Genetic Medicine
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Scribe Therapeutics
Deal Size : $1,575.0 million
Deal Type : Collaboration
Details : Under the collaboration, Prevail gets exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified genetic targets known to cause serious neurological and neuromuscular diseases.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $75.0 million
May 16, 2023
Lead Product(s) : CRISPR-based Genetic Medicine
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Scribe Therapeutics
Deal Size : $1,575.0 million
Deal Type : Collaboration
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Neurology
Study Phase : Preclinical
Recipient : Capsida
Deal Size : $740.0 million
Deal Type : Collaboration
Details : Delivering AAV gene therapy systemically to target the CNS, while limiting exposure to non-target organs (such as the liver), has been a significant challenge in the gene therapy field.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : $55.0 million
January 04, 2023
Lead Product(s) : AAV-based Gene Therapy
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Recipient : Capsida
Deal Size : $740.0 million
Deal Type : Collaboration
Lead Product(s) : AAV Capsid-based Therapeutic
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : Lacerta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases. As a part of the collaboration, Prevail will receive rights to utilize one of Lacerta’s novel AAV capsids for select undisclosed CNS targets.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
August 23, 2022
Lead Product(s) : AAV Capsid-based Therapeutic
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : Lacerta Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Completes Acquisition of Prevail Therapeutics
Details : Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenera...
Brand Name : PR001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 22, 2021
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lilly Announces Agreement to Acquire Prevail Therapeutics
Details : Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disea...
Brand Name : PR001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Eli Lilly
Deal Size : $1,040.0 million
Deal Type : Acquisition
Lead Product(s) : PR006,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Brand Name : PR006
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 30, 2020
Lead Product(s) : PR006,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for...
Brand Name : PR001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 18, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Brand Name : PR001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 27, 2020
Lead Product(s) : PR001,Methylprednisolone,Sirolimus
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?